{"schema_version":"secwatch.filing_event.v1","accession":"0000879169-26-000023","form_type":"8-K","ticker":"INCY","cik":"0000879169","company_name":"INCYTE CORP","filed_at":"2026-04-28T23:59:59+00:00","discovered_at":"2026-05-14T18:02:33.852571+00:00","generated_at":"2026-05-15T03:31:41.451524+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Incyte Q1 revenue $1.27B (+21% YoY), Non-GAAP EPS $1.81 beats prior $1.16; pipeline expands","bullets":["Total net sales $1.10B (+20% YoY); Jakafi $758M (+7%), Opzelura $143M (+20%), Hem/Onc $204M (+116%).","GAAP net income $303M ($1.47 diluted EPS) vs $158M ($0.80) prior year; Non-GAAP diluted EPS $1.81.","Positive Phase 3 vitiligo results for povorcitinib; NDA accepted for HS; four product approvals/launches expected in next 12 months.","Appointed Suketu Upadhyay as CFO effective May 4, 2026; cash position $4.0B.","FY 2026 guidance reaffirmed: total net sales $4.77-$4.94B; R&D and SG&A expenses guided."],"urls":{"canonical":"https://secwatch.observer/filing/0000879169-26-000023","json":"https://secwatch.observer/filing/0000879169-26-000023.json","markdown":"https://secwatch.observer/filing/0000879169-26-000023.md","text":"https://secwatch.observer/filing/0000879169-26-000023.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/879169/000087916926000023/0000879169-26-000023-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/879169/000087916926000023/incy-20260428.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T03:31:41.451524+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9ff183224b423976228267910b1e8edb86352a61","claim":"INCYTE CORP reported first quarter of 2026 results: revenue $1.27 billion.","evidence_excerpt":"furnished as Exhibit 99.1. --- EX-99.1 (EX-99.1) --- FOR IMMEDIATE RELEASE Incyte Reports First Quarter 2026 Financial Results and Provides Business Updates Total revenue of $1.27 billion and total net sales of $1.10 billion in the first quarter of 2026, an increase of 21% and 20% respectively, compared to the first quarter of 2025 Jakafi ® (ruxolitinib) net sales","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/879169/000087916926000023/0000879169-26-000023-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter of 2026"},{"label":"Revenue","value":"$1.27 billion"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}